Close Menu
    Bahrain CourantBahrain Courant
    • Home
    • Contact Us
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Bahrain CourantBahrain Courant
    Home » Qiming Venture Partners Welcomes Apollomics’ Successful IPO on Nasdaq
    PR Newswire

    Qiming Venture Partners Welcomes Apollomics’ Successful IPO on Nasdaq

    March 31, 2023
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    SHANGHAI, March 31, 2023 /PRNewswire/ — On March 30, 2023, Apollomics Inc. (“Apollomics”), an innovative biopharmaceutical company and portfolio company of Qiming Venture Partners, listed on Nasdaq through a SPAC merger with Maxpro Capital Acquisition Corp. The combined company is now traded under the symbol APLM with an issue price of $10.00/share and an opening price of $18.60/share, up by 172% at closing price on the first day, representing a market cap of $2.6 billion.

    Qiming Venture Partners is one of the earliest investors of Apollomics, accompanying the company growth since its Pre-A round. Apollomics’ IPO marks Qiming’s 5th IPO since 2023.

    Founded in 2015, Apollomics is committed to the discovery and development of mono- and combination-oncology therapies for cancer treatment. The company has built a pipeline includes nine novel oncology drug candidates, six of which are currently in clinical stage of development. By using targeted therapy, immuno-oncology agents, and other innovative approaches, Apollomics’ novel drug candidates have the potential to address a range of cancers, including lung cancer, brain cancer, acute myeloid leukemia, and other solid tumors.

    The company has achieved breakthroughs in recent years. In 2022, the US FDA has granted Orphan Drug Designation to vebreltinib (APL-101), a highly specific cMet inhibitor, in non-small cell lung cancer and other solid tumors with cMet dysregulation. Apollomics expects results from its global Phase 2 multi-cohort clinical trial this year, which may support its first new drug application with the US FDA while generating clinical data on other indications.

    Apollomics is also developing uproleselan (APL-106), an E-selectin inhibitor, in China as an adjunct to chemotherapy to enhance its anti-cancer effects for adult patients with relapsed or refractory acute myeloid leukemia. Uproleselan (APL-106) has received Breakthrough Therapy Designation by the US FDA and the China National Medical Products Administration (NMPA). And the company expects to complete patient recruitment of its Phase 3 study in China this year.

    “Becoming a public company represents a major milestone in our journey to provide solutions for patients with difficult-to-treat cancers worldwide,” said Dr. Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics. “The funds now available to us are expected to facilitate development of our oncology pipeline and further our mission to provide patients with effective therapies and hope.”

    “Apollomics team has been working diligently to develop innovative cancer therapies and has built an extensive pipeline. We believe the successful IPO debut today will help the company further expand clinical trials and invest in research and development, continuously making groundbreaking strides in the field of cancer treatment. The core value of innovative drugs is to address unmet clinical needs, and Qiming will continue to focus on this area, benefiting more patients worldwide.” said Nisa Leung, Managing Partner of Qiming Venture Partners.

    About Qiming Venture Partners

    Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and the San Francisco Bay Area.

    Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.4 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.

    Since our debut, we have backed over 480 fast-growing and innovative companies. Over 180 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange or Shenzhen Stock Exchange, or through M&A or by other means. There are also over 70 portfolio companies that have achieved unicorn status.

    Many of our portfolio companies are today’s most influential firms in their respective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, New Horizon Health, Venus MedTech, Sanyou Medical, AmoyDx, Berry Genomics, SinocellTech, Yuanxin Technology, Caidya, Belief BioMed, WeRide, Biren Technology and UBTech among many others.

    Cision View original content:https://www.prnewswire.co.uk/news-releases/qiming-venture-partners-welcomes-apollomics-successful-ipo-on-nasdaq-301786975.html

    Related Posts

    Ali Al Nuaimi at Ajman Media Forum: Credibility and trust are the foundations of influential media

    November 19, 2026

    Ajman Media Forum explores who leads government messaging in the age of algorithms

    November 19, 2026

    Abdulla Al Hamed at Ajman Media Forum 2026: Credibility is the foundation of a strong media sector and protects communities in times of crisis

    November 19, 2026

    Ammar bin Humaid Inaugurates First Ajman Media Forum 2026, “The Signal”

    November 19, 2026

    WeWalk returns to Dubai Science Park in support of children with diabetes

    November 19, 2026

    DAR GLOBAL AND THE TRUMP ORGANIZATION MARK SUCCESSFUL LAUNCH OF $700M QATAR DESTINATION TO INTERNATIONAL INVESTORS

    November 19, 2026
    Daily Update

    Botswana opens consultations on proposed 33 percent hike now

    November 19, 2026

    PM Modi meets Prince and Princess of Wales for climate talks

    November 19, 2026

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026

    Dubai Airports expects over 70 million guests in 2026

    November 18, 2026

    Prabowo says DEFA can unlock $2 trillion ASEAN digital economy

    November 18, 2026

    Over 9 million visitors lift Tunisia tourism income 3.4%

    November 17, 2026

    Sheikh Mohamed receives Venezuela’s Delcy Rodríguez in Abu Dhabi

    November 17, 2026
    © 2026 Bahrain Courant | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.